FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 322:89-94 January 11, 1990 Number 2 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

In a randomized, double-blind, placebo-controlled study, we assessed the efficacy of an ACTH(4-9) analogue, Org 2766, in the prevention of cisplatin neuropathy in 55 women with ovarian cancer. The analogue was given subcutaneously in a dose of 0.25 mg (low dose) or 1 mg (high dose) per square meter of body-surface area before and after treatment with cisplatin and cyclophosphamide (75 and 750 mg per square meter every three weeks). The threshold of vibration perception was used as the principal measure of neurotoxicity. After four cycles of chemotherapy, the mean (+/- SEM) threshold value for vibration perception in the placebo group increased from 0.67 +/- 0.12 to 1.61 +/- 0.43 microns of skin displacement (P less than 0.0001). In the high-dose treatment group, there was no increase in the threshold value after four cycles (from 0.54 +/- 0.12 to 0.50 +/- 0.06 micron). After six cycles of chemotherapy, the threshold value was 5.87 +/- 1.97 microns in the placebo group (more than an eight-fold increase from base line), as compared with 0.88 +/- 0.17 micron (less than a twofold increase) in the high-dose treatment group (P less than 0.005). In the high-dose group, fewer neurologic signs and symptoms were recorded than in the placebo group. With the lower dose of the analogue, these protective effects were less prominent. No side effects were seen after treatment with Org 2766. The rates of clinical response to chemotherapy were similar in all groups. These results suggest that Org 2766 can prevent or attenuate cisplatin neuropathy without adversely affecting the cytotoxic effect of the drug.

Source Information

Department of Oncology, Utrecht University Hospital, The Netherlands.

This article has been cited by other articles:

• McWhinney, S. R., Goldberg, R. M., McLeod, H. L. (2009). Platinum neurotoxicity pharmacogenetics. Molecular Cancer Therapeutics 8: 10-16 [Abstract] [Full Text]  
• Wen, P. Y. (2005). A Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of Recombinant Human Leukemia Inhibitory Factor (rhuLIF, emfilermin, AM424) to Prevent Chemotherapy-Induced Peripheral Neuropathy. Clin. Cancer Res. 11: 1685-1686 [Full Text]  
• Catania, A., Gatti, S., Colombo, G., Lipton, J. M. (2004). Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation. Pharmacol. Rev. 56: 1-29 [Abstract] [Full Text]  
• Grolleau, F., Gamelin, L., Boisdron-Celle, M., Lapied, B., Pelhate, M., Gamelin, E. (2001). A Possible Explanation for a Neurotoxic Effect of the Anticancer Agent Oxaliplatin on Neuronal Voltage-Gated Sodium Channels. J. Neurophysiol. 85: 2293-2297 [Abstract] [Full Text]  
• Summerhayes, M. (1995). Review : Amifostine and other chemoprotective agents in cancer chemotherapy: A brief review. J Oncol Pharm Pract 1: 21-31 [Abstract]  
• Apfel, S. C., Kessler, J. A. (1995). Peripheral Neuropathies: Will Growth Factors Be Effective as Therapies?. Neuroscientist 1: 176-182 [Abstract]  
• van Kooten, B., van Diemen, H. A. M., Groenhout, K. M., Huijgens, P. C., Ossenkoppele, G. J., Nauta, J. J. P., Heimans, J. J. (1992). A Pilot Study on the Influence of a Corticotropin (4-9) Analogue on Vinca Alkaloid--Induced Neuropathy. Arch Neurol 49: 1027-1031 [Abstract]  
• Durivage, H. J., Burnham, N. L. (1991). Prevention and Management of Toxicities Associated With Antineoplastic Drugs. Journal of Pharmacy Practice 4: 27-48